Inicia sesión Registrate Mi Biblioteca idioma

Idioma

biblioteca idioma abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará la selección de artículos sobre Trastornos del Movimiento clasificados según los 11 tipos establecidos por International Parkinson & Movement Disorder Society.

Corea y enfermedad de Huntington

347 ARTíCULOS , VIENDO DEL 16 AL 30

PUBMED

OPTICAL COHERENCE TOMOGRAPHY (OCT) STUDY IN ARGENTINEAN HUNTINGTON'S DISEASE PATIENTS.

Gatto E, Parisi V, Persi G, Rey EF, Cesarini M, Etcheverry JL, Rivera P, Squitieri F.

Int J Neurosci. 2018 Jun 18:1-18. doi: 10.1080/00207454.2018.1489807. [Epub ahead of print]

0

0

0

PUBMED

Studying Huntington's Disease in Yeast: From Mechanisms to Pharmacological Approaches.

Hofer S, Kainz K, Zimmermann A, Bauer MA, Pendl T, Poglitsch M, Madeo F, Carmona-Gutierrez D.

Front Mol Neurosci. 2018 Sep 4;11:318. doi: 10.3389/fnmol.2018.00318. eCollection 2018. Review.

0

0

0

PUBMED

Clinical and genetic characteristics of late-onset Huntington's disease.

Oosterloo M, Bijlsma EK, van Kuijk SM, Minkels F, de Die-Smulders CE; REGISTRY Investigators of the European Huntington's Disease Network.; Registry Steering committee.; Language coordinators.; EHDN's

Parkinsonism Relat Disord. 2018 Nov 29. pii: S1353-8020(18)30490-5. doi: 10.1016/j.parkreldis.2018.11.009. [Epub ahead of print]

0

0

0

PUBMED

Chorea revealing systemic lupus erythematosus in a 13-year old boy: A case report and short review of the literature.

Athanasopoulos E, Kalaitzidou I, Vlachaki G, Stefanaki S, Tzagkaraki A, Niotakis G, Tritou I, Ladomenou F.

Int Rev Immunol. 2018 Mar 29:1-6. doi: 10.1080/08830185.2018.1452920. [Epub ahead of print]

0

0

0

PUBMED

Drp1/Fis1-mediated mitochondrial fragmentation leads to lysosomal dysfunction in cardiac models of Huntington's disease.

Joshi AU, Ebert AE, Haileselassie B, Mochly-Rosen D.

J Mol Cell Cardiol. 2018 Dec 11;127:125-133. doi: 10.1016/j.yjmcc.2018.12.004. [Epub ahead of print]

0

0

0

PUBMED

High and Low Levels of an NTRK2-Driven Genetic Profile Affect Motor- and Cognition-Associated Frontal Gray Matter in Prodromal Huntington's Disease.

Ciarochi JA, Liu J, Calhoun V, Johnson H, Misiura M, Bockholt HJ, Espinoza FA, Caprihan A, Plis S, Turner JA, Paulsen JS; PREDICT-HD Investigators and Coordinators of the Huntington Study Group..

Brain Sci. 2018 Jun 22;8(7). pii: E116. doi: 10.3390/brainsci8070116.

0

0

0

PUBMED

An Update on the Treatment of Chorea.

Feinstein E, Walker R.

Curr Treat Options Neurol. 2018 Sep 25;20(10):44. doi: 10.1007/s11940-018-0529-y. Review.

0

0

0

PUBMED

Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study.

Reilmann R, McGarry A, Grachev ID, Savola JM, Borowsky B, Eyal E, Gross N, Langbehn D, Schubert R, Wickenberg AT, Papapetropoulos S, Hayden M, Squitieri F, Kieburtz K, Landwehrmeyer GB; European Hunti

Lancet Neurol. 2018 Dec 14. pii: S1474-4422(18)30391-0. doi: 10.1016/S1474-4422(18)30391-0. [Epub ahead of print]

0

0

0

PUBMED

Azadiradione Restores Protein Quality Control and Ameliorates the Disease Pathogenesis in a Mouse Model of Huntington's Disease.

Singh BK, Vatsa N, Nelson VK, Kumar V, Kumar SS, Mandal SC, Pal M, Jana NR.

Mol Neurobiol. 2018 Jan 2. doi: 10.1007/s12035-017-0853-3. [Epub ahead of print]

0

0

0

PUBMED

Evaluation of Cognition and Cortical Excitability in Huntington's Disease.

Kamble N, Netravathi M, Nagaraju BC, Lenka A, Kumar K, Sowmya V, Jain S, Pal PK.

Can J Neurol Sci. 2018 Jan 8:1-6. doi: 10.1017/cjn.2017.277. [Epub ahead of print]

0

0

0

PUBMED

Pallidal deep brain stimulation in juvenile Huntington's disease: local field potential oscillations and clinical data.

Ferrea S, Groiss SJ, Elben S, Hartmann CJ, Dunnett SB, Rosser A, Saft C, Schnitzler A, Vesper J, Wojtecki L; Surgical Approaches Working Group of the European Huntington’s Disease Network (EHDN)..

J Neurol. 2018 May 3. doi: 10.1007/s00415-018-8880-1. [Epub ahead of print]

0

0

0

PUBMED

Patient-Specific iPSC-Based Models of Huntington's Disease as a Tool to Study Store-Operated Calcium Entry Drug Targeting.

Vigont V, Nekrasov E, Shalygin A, Gusev K, Klushnikov S, Illarioshkin S, Lagarkova M, Kiselev SL, Kaznacheyeva E.

Front Pharmacol. 2018 Jun 29;9:696. doi: 10.3389/fphar.2018.00696. eCollection 2018.

0

0

0

PUBMED

Indoleamine 2,3-dioxygenase as a novel therapeutic target for Huntington's disease.

Boros FA, Klivényi P, Toldi J, Vécsei L.

Expert Opin Ther Targets. 2018 Nov 22:1-13. doi: 10.1080/14728222.2019.1549231. [Epub ahead of print]

0

0

0

PUBMED

SIRT1 is increased in affected brain regions and hypothalamic metabolic pathways are altered in Huntington disease.

Baldo B, Gabery S, Soylu-Kucharz R, Cheong RY, Henningsen JB, Englund E, McLean C, Kirik D, Halliday G, Petersén Å.

Neuropathol Appl Neurobiol. 2018 Jul 18. doi: 10.1111/nan.12514. [Epub ahead of print]

0

0

0

PUBMED

Increased oxidative stress and CaMKII activity contribute to electro-mechanical defects in cardiomyocytes from a murine model of Huntington's disease.

Joviano-Santos JV, Santos-Miranda A, Botelho AFM, de Jesus ICG, Andrade JN, de Oliveira Barreto T, Magalhães-Gomes MPS, Valadão PAC, Dos Santos Cruz J, Melo MM, Guatimosim S, Guatimosim C.

FEBS J. 2018 Nov 19. doi: 10.1111/febs.14706. [Epub ahead of print]

0

0

0

Comentarios

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo HONcode Logo WIS

En colaboración con:

Zambon Neuroacademy